Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights)
2022 · Asset Purchase · $1.1B · Complete
Announcement Sentiment
82
Strongly positive
Regeneron acquired Sanofi's stake in their Libtayo (cemiplimab) collaboration, gaining exclusive worldwide development, commercialization and manufacturing rights. Sanofi received $900M upfront, an 11% royalty on worldwide net sales, a $100M regulatory milestone, and up to $100M in sales-related milestones over two years. Closed July 1, 2022.